BiotechTube

Aflibercept (Eylea, BAY86-5321)

Pre-clinicalCompleted
0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Choroidal Neovascularization

Conditions

Choroidal Neovascularization, Macular Degeneration

Trial Timeline

Jul 1, 2016 → Dec 13, 2019

NCT ID
NCT02821247

About Aflibercept (Eylea, BAY86-5321)

Aflibercept (Eylea, BAY86-5321) is a pre-clinical stage product being developed by Bayer for Choroidal Neovascularization. The current trial status is completed. This product is registered under clinical trial identifier NCT02821247. Target conditions include Choroidal Neovascularization, Macular Degeneration.

What happened to similar drugs?

7 of 16 similar drugs in Choroidal Neovascularization were approved

Approved (7) Terminated (0) Active (9)
✅Verteporfin Photodynamic Therapy + RanibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅Intravitreal aflibercept injection 2.0mgRegeneron PharmaceuticalsApproved
✅Rescue Intravitreal Aflibercept InjectionRegeneron PharmaceuticalsApproved
✅Aflibercept Intravitreous InjectionBayerApproved
✅afliberceptBayerApproved

Hype Score Breakdown

Clinical
3
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (8)

NCT IDPhaseStatus
NCT06929143Pre-clinicalActive
NCT05705258Pre-clinicalRecruiting
NCT04519619Pre-clinicalRecruiting
NCT03939767Pre-clinicalCompleted
NCT03290794Pre-clinicalCompleted
NCT02821247Pre-clinicalCompleted
NCT02800642ApprovedCompleted
NCT02425501Pre-clinicalCompleted

Competing Products

20 competing products in Choroidal Neovascularization

See all competitors
ProductCompanyStageHype Score
Zimura + EyleaAstellas PharmaPhase 2
27
Avacincaptad PegolAstellas PharmaPhase 2
35
Verteporfin Photodynamic Therapy + RanibizumabNovartisApproved
43
ranibizumabNovartisApproved
43
RanibizumabNovartisApproved
43
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
40
ranibizumabNovartisPhase 3
40
Everolimus + RanibizumabNovartisPhase 2
27
RanibizumabNovartisPhase 3
40
ranibizumab 0.5mgNovartisPhase 2
35
ranibizumabNovartisPhase 3
40
Brolucizumab 6mg + Brolucizumab 6mgNovartisPhase 3
40
Intravitreal injection ranibizumabNovartisPhase 2
35
RanibizumabNovartisPhase 3
40
RanibizumabNovartisPhase 1/2
32
Faricimab + Ranibizumab + Sham ProcedureRochePhase 2
35
Faricimab + RanibizumabRochePhase 3
44
Faricimab + Ranibizumab + Sham ProcedureRochePhase 2
35
Intravitreal PegaptanibPfizerPre-clinical
18
Intravitreal aflibercept injection 2.0mgRegeneron PharmaceuticalsApproved
43